<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/insider-buying-iveric-bio-inc-nasdaqisee-ceo-buys-15000-shares-of-stock.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T07:08:41+00:00"/>
    <meta property="og:title" content="Insider Buying: IVERIC bio Inc (NASDAQ:ISEE) CEO Buys 15,000 Shares of Stock"/>
    <meta property="og:description" content="IVERIC bio Inc (NASDAQ:ISEE) CEO Glenn Sblendorio purchased 15,000 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was bought at an average price of $3.12 per share, for a total transaction of $46,800.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be […]"/>
  </head>
  <body>
    <article>
      <h1>Insider Buying: IVERIC bio Inc (NASDAQ:ISEE) CEO Buys 15,000 Shares of Stock</h1>
      <address><time datetime="2019-11-21T07:08:41+00:00">21 Nov 2019, 07:08</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/generic-stocks.jpg"/>
      </figure>
      <p>IVERIC bio Inc (NASDAQ:ISEE) CEO Glenn Sblendorio purchased 15,000 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was bought at an average price of $3.12 per share, for a total transaction of $46,800.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/1277478/000110465919065146/xslF345X03/a4.xml">the SEC website</a>.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/ISEE/insider-trades/">NASDAQ ISEE</a> opened at $3.48 on Thursday. The firm has a market capitalization of $128.15 million, a price-to-earnings ratio of -2.08 and a beta of 1.53. The company’s fifty day moving average is $2.06 and its two-hundred day moving average is $1.45. IVERIC bio Inc has a 52-week low of $0.91 and a 52-week high of $4.36.</p>
      <p>IVERIC bio (NASDAQ:ISEE) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter. Sell-side analysts forecast that IVERIC bio Inc will post -1.4 earnings per share for the current year.</p>
      <p>ISEE has been the topic of several research analyst reports. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=ISEE">ValuEngine</a> lowered shares of IVERIC bio from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 30th. Chardan Capital restated a “hold” rating and issued a $1.25 price target on shares of IVERIC bio in a research report on Wednesday, September 18th.</p>
      <p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Stonepine Capital Management LLC acquired a new stake in IVERIC bio in the 2nd quarter worth $5,348,000. Tamarack Advisers LP acquired a new stake in IVERIC bio in the 2nd quarter worth $3,720,000. Acadian Asset Management LLC acquired a new stake in IVERIC bio in the 2nd quarter worth $1,636,000. Renaissance Technologies LLC acquired a new stake in IVERIC bio in the 2nd quarter worth $1,604,000. Finally, Vanguard Group Inc. acquired a new stake in IVERIC bio in the 2nd quarter worth $1,476,000. Institutional investors own 38.76% of the company’s stock.</p>
      <p>
        <b>About IVERIC bio</b>
      </p>
      <p>IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/guidelines-for-successful-channel-trading/">Key terms to understand channel trading</a></p>
    </article>
  </body>
</html>